<DOC>
	<DOCNO>NCT01962454</DOCNO>
	<brief_summary>This single-blind , randomize placebo-controlled , parallel study , study volunteer blind testosterone/placebo treatment . This study test relatively new , less invasive method collect muscle tissue determine method appropriate collect muscle sample assessment fractional synthetic rate ( FSR ) muscle-derived protein . This study also investigate whether FSR protein may serve early biomarkers muscle anabolism , know anabolic agent ( testosterone ) administer healthy , elderly male subject 3 week period . The fractional synthetic rate several muscle-derived protein analyze Baseline period testosterone treatment use deuterium label protein incorporation deuterium deuterated water ( D2O ) .</brief_summary>
	<brief_title>A Study Evaluate Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Males age 6075 age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include find unlikely introduce additional risk factor interfere study procedure . Ambulatory outside home , stable chronic condition allow ( clinically significant change major medication adjustment previous 3 month ) hypertension and/or dyslipidemia . Subjects must able satisfactorily complete low extremity 1repetition maximum leg press assessment . Body weight &gt; =50 kilogram body mass index within range 20 34 kilogram per square meter ( inclusive ) Renal clearance &gt; = 45 milliliter per minute base estimate Glomerular Filtration Rate ( eGFR ) calculate abbreviated MDRD equation , use serum creatinine demographic data obtain Screening . Capable give write informed consent , include compliance requirement restriction list consent form ALT , alkaline phosphatase bilirubin = &lt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Averaged correct QT interval ( QTc ) value 3 electrocardiogram separate 35 minute period : Bazett 's QTc ( QTcB ) Fridericia 's QTc ( QTcF ) &lt; 460 msec ; QTcB QTcF &lt; 480 msec subject Partial Bundle Branch Block . Subjects history clinically significant endocrine , gastrointestinal , cardiovascular , neurological , haematological , immunological , renal , respiratory , vertigo , dizziness , prostate enlargement , genitourinary abnormality diseases Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History muscular neuromuscular disease multiple sclerosis , myasthenia gravis , muscular dystrophy , amyotrophic lateral sclerosis , stroke transient ischemic attack Hospitalization past 6 month Current recent use ACEinhibitors and/or systemic steroid Diabetes ( Type 1 , Type 2 ) History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male . One drink equivalent 12 gram alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . History sensitivity local anaesthetic , study diagnostic reagent , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History bleed disorder , include thrombocytopenia coagulopathies , current use anticoagulant . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus antibody . Electrolytes Sodium +5 milliequivalent per liter ( mEq/L ) outside normal reference range , Potassium Calcium 10 % outside normal reference range ( &lt; 0.9 x low limit normal [ LLN ] &gt; 1.1 x ULN ) Metabolic Glucose 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) Total Cholesterol &gt; 240 milligram per deciliter Muscle creatine phosphokinase &gt; 2.0 x ULN Hematology Hemoglobin , White blood cell , Neutrophils , Platelets 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) A pro time/prothrombin time test ( PT/PTT ) outside normal reference range assay . Prostate Specific Antigen ( PSA ) &gt; =3.0 nanogram per milliliter Significant prostate enlargement upon clinical examination . Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first deuterated water ( D2O ) dose day Runin Phase current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first D2O dose day Runin Phase .</criteria>
	<gender>Male</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>D2O</keyword>
	<keyword>Microbiopsy</keyword>
	<keyword>dynamic proteomics</keyword>
	<keyword>muscle mass</keyword>
	<keyword>testosterone</keyword>
	<keyword>Duke University</keyword>
	<keyword>skeletal muscle</keyword>
</DOC>